You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神州細胞(688520.SH):控股子公司產品SCT640C獲得藥物臨牀試驗批准通知書
格隆匯 07-24 15:58

格隆匯7月24日丨神州細胞(688520.SH)公佈,近日,北京神州細胞生物技術集團股份公司控股子公司神州細胞工程有限公司收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,同意公司自主研發的產品SCT640C注射液開展成人類風濕關節炎適應症的臨牀試驗。類風濕關節炎(RheumatoidArthritis,RA)是一種系統性自身免疫性疾病,以慢性侵蝕性關節炎為主要臨牀表現,是一種高致殘性疾病,可併發肺部疾病、心腦血管疾病、骨質疏鬆、惡性腫瘤等。RA的全球發病率約為0.5%~1%,我國大陸地區發病率約為0.4~2%,據此估計目前我國RA患者超過500萬人。SCT640C產品為公司以差異化競爭優勢為目標自主研發的用於自身免疫性疾病治療的單克隆抗體注射液。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account